Hypothesis-driven clinical studies

This survey aims to gather clinical follow-up data for our hypothesis-driven studies, focusing on real-world patients profiled with Canine CGP and treated with genomics-based therapy

Patient Information

Pet Name

First

Last

Pet Date of Birth (DOB)

VetOmics ID

e.g. VOC25020099

Patient Treatment History

1. Was any treatment treatment given PRIOR TO VetOmics test??

No treatment was given prior
Surgery
Conventional (non-targeted) chemotherapy. This includes both high- and low-dose (metronomic) chemotherapy.
Radiation Therapy
Targeted Therapy (e.g. Toceranib, Rapamycin, Trametinib)
Immunotherapy (e.g. gilvetmab, melanoma vaccine, torigen vaccine)
Electrochemotherapy
OTHER

OTHER: Please Sepcify

Please specify treatments PRIOR TO VetOmics test: please provide the start date(s) (MM/DD/YYYY), dosing and schedule, following the therapy name

I still think we should keep this, so that we have a PFS prior to vetomics testing, this almost serves as control arm, e.g. without genomic-guided therapy, this is the PFS. e.g. Doxorubicin, 12/18/2022

2. What was the best response of treatment PRIOR TO VetOmics-guided therapy?

3. Did the cancer progress prior to VetOmics-guided therapy?

Yes
No
Not evaluated yet

4. When was progression documented with treatment piror to VetOmics test?

5. Was the patient treated with VetOmics-guided therapy?

Yes
No

6. What was the reason for not treating the patient based on VetOmics-guided therapy?

If "OTHER", please specify

The following questions apply to VetOmics-guided therapy

7. What was the first VetOmics-guided therapy or combination used?

If "OTHER", please specify

8. When was the first VetOmics-guided therapy started?

9. What was the best response?

10. When was progression documented?

11. What was the duration of this response (in days)?

12. Was the patient treated with the second VetOmics-guided therapy?

Yes
No

13. What was the second VetOmics-guided therapy or combination used?

If "OTHER", please specify

14. When was the second VetOmics-guided therapy started?

15. What was the best response?

16. When was progression documented?

17. What was the duration of this response (in days)?

18. Was the patient treated with the third VetOmics-guided therapy?

Yes
No

19. What was the third VetOmics-guided therapy or combination used?

If "OTHER", please specify

20. When was the third VetOmics-guided therapy started?

When VetOmics-guided specify

21. What was the best response?

22. When was progression documented?

23. What was the duration of this response (in days)?

24. Any additional therapy and progression: please provide the start date(s) (MM/DD/YYYY) and progression date(s) (MM/DD/YYYY), dosing and schedule, following the therapy name

e.g. gilvetmab, started 11/06/2023, progressed 1/10/2024

Patient Current Status

25. Alive or Deceased

Alive
Deceased
Lost to follow-up (LTFU)

26. Alive: Date of last visit or last contact, whichever is the most recent

27. Lost to follow-up (LTFU): Date of last visit or last contact, whichever is the most recent

28. Deceased: Date of death or last contact

29. Type and cause of death

Hypothesis-driven clinical studies

Patient Information

Patient Treatment History

The following questions apply to VetOmics-guided therapy

Patient Current Status

Thank you for your time! We look forward to supporting you and your patient on this journey.